SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

ianalumab

NVS·NOVARTIS AG
MIXED
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Uncertain for Sjögren's, submission status unclear as of Oct 2026; if filed, potential FDA decision in H2 2027. ITP submission planned for 2027 pending VAYHIT1 data. SLE likely 2028 or later.
Why 4/10
No confirmed dated binary catalyst in the next ~12 months: the Sjögren's regulatory submission status is uncertain (originally planned for Q3 2026 but not confirmed as filed), and the ITP submission is planned for 2027 without a specific date. Ianalumab is one of many pipeline assets at a large-cap pharma (Novartis), limiting single-drug share-price impact.
Actionable Insight MIXED

Watch for any Novartis announcement confirming the Sjögren's regulatory submission, if filed, a PDUFA date would likely land in H2 2027. Also monitor VAYHIT1 topline data (first-line ITP), which could trigger the ITP regulatory submission in 2027. The NEJM publication and mixed efficacy signal may increase regulatory uncertainty.

Price Chart

Loading chart...

Executive Summary

Ianalumab (VAY736) is Novartis' investigational anti-BAFF-R monoclonal antibody being developed primarily for Sjögren's disease, with additional programs in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE). Two Phase 3 trials in Sjögren's (NEPTUNUS-1 and -2) met their primary endpoint of reduced disease activity, but the modest effect size and lack of clear benefit on patient-reported symptoms, published in NEJM on October 22, 2026, have raised questions about the regulatory path. The FDA granted Breakthrough Therapy designation in January 2026, but the planned global submission (originally early 2026, then pushed to Q3 2026) has not been confirmed as filed. A new Phase 3 trial (THALASSA) targeting high-symptom-burden patients started in July 2026. In ITP, the VAYHIT2 trial was positive, and Novartis plans to submit for FDA approval in 2027 pending VAYHIT1 data. For a large-cap pharma like Novartis, ianalumab is one of many pipeline assets, so any single-catalyst impact is limited.

How It Works

Ianalumab is a lab-engineered antibody that targets and blocks BAFF-R, a protein on the surface of B-cells (a type of immune cell). It works through a dual mechanism: it directly kills B-cells and also blocks signals that keep B-cells alive and active. Since overactive B-cells drive autoimmune diseases like Sjögren's, ITP, and lupus, reducing their activity can dampen the misguided immune attack.

Trial Status

Two Phase 3 trials in Sjögren's disease (NEPTUNUS-1, NEPTUNUS-2) completed and published in NEJM (Oct 2026), met primary endpoint with modest effect. A third Phase 3 trial in Sjögren's (THALASSA, high-symptom-burden patients) began July 2026. In ITP, Phase 3 VAYHIT2 met its primary endpoint (Aug 2025, published NEJM Apr 2026); VAYHIT1 (first-line ITP) is ongoing. Two Phase 3 SLE trials (SIRIUS-SLE 1 and 2) are ongoing/recruiting.

The Two-Sided Case

▲ Bull Case5
First-ever targeted therapy for Sjögren's disease, a multi-billion-dollar unmet need with no approved disease-modifying treatments
Phase 3 NEPTUNUS trials met primary endpoint (ESSDAI reduction) in replicate studies, a first for any drug in Sjögren's
FDA Breakthrough Therapy designation (Jan 2026) provides accelerated development and rolling review pathway
Positive Phase 3 data in ITP (VAYHIT2) with disease-modifying potential opens a second sizable market; Orphan Drug status in both US and EU
Dual mechanism (B-cell depletion + BAFF-R blockade) differentiates from earlier failed B-cell targeting approaches
▼ Bear Case5
NEJM-published data (Oct 22, 2026) showed only modest 1-1.3 point ESSDAI improvement vs placebo; key secondary endpoints like patient-reported symptoms did not reach statistical significance
Regulatory submission for Sjögren's was pushed from early 2026 to Q3 2026, and as of late October 2026 it remains unclear whether the filing was actually made, creating timeline uncertainty
High placebo response in NEPTUNUS trials complicates the efficacy signal and may give FDA pause
New Phase 3 trial (THALASSA) launched in July 2026 suggests Novartis may be gathering additional data rather than relying solely on NEPTUNUS for approval
For Novartis (a $200B+ market cap pharma), ianalumab is one of 100+ pipeline projects, even a major approval would have limited impact on the overall stock

Upcoming Catalysts

  • Confirmation of Sjögren's regulatory submission (status unclear as of Oct 2026)
  • VAYHIT1 (first-line ITP) Phase 3 topline data, expected 2026/2027
  • Potential PDUFA date if Sjögren's BLA is filed
  • SIRIUS-SLE Phase 3 readouts (timeline unknown)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 11

Hover a chip for the title
1 novartis.com2 novartis.com3 nejm.org4 medpagetoday.com5 novartis.com6 nejm.org7 fiercebiotech.com8 clinicaltrials.gov9 novartis.com10 en.wikipedia.org11 theclinicaltimes.com